Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Cynvenio's ClearID; Natera's Panorama; Verinata's Verifi; More


Cynvenio has launched its ClearID Breast Cancer monitoring program that consists two tests — one that screens for the presence of circulating tumor cells in a patient's blood and a second test that uses next-generation sequencing to target more than 4,500 mutations in 50 cancer genes in those circulating tumor cells (CSN 4/10/2013).

Natera has expanded its Panorama test to include detection of triploidy, along with the fetal aneuploidies trisomy 21, trisomy 18, trisomy 13, and monosomy X. Additionally, the test now has a turnaround time of between seven and 10 days.

Illumina's Verinata Health has expanded the use of its noninvasive prenatal fetal aneuploidy test, Verifi, to women pregnant with twins. The test can detect trisomy 21, trisomy 18, trisomy 13, and the presence of a Y chromosome in twin fetuses.

Qiagen has launched Empowered Genome Community, an initiative to enable individuals who have had their genomes sequenced to share, explore, and interpret their data with researchers and each other. Participants can join online here, and will be able to use Qiagen's Ingenuity Variant Analysis platform to interpret their genomes and retain full ownership and control over their data.